Avid Bioservices (NASDAQ:CDMO) fell ~8% Friday afternoon after the biologics company reported mixed FQ1’24 results and maintained full-year guidance.
Q1 GAAP EPS of -$0.03 misses by $0.01 and revenue of $37.7M (+2.7% Y/Y) beats by $1.61M.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased